8 research outputs found

    Researching COVID to Enhance Recovery (RECOVER) Adult Study Protocol: Rationale, Objectives, and Design

    Get PDF
    IMPORTANCE: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis. METHODS: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms. DISCUSSION: RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options

    Chitosan Composites Synthesized Using Acetic Acid and Tetraethylorthosilicate Respond Differently to Methylene Blue Adsorption

    No full text
    The sol-gel and cross-linking processes have been used by researchers to synthesize silica-based nanostructures and optimize their size and morphology by changing either the material or the synthesis conditions. However, the influence of the silica nanostructures on the overall physicochemical and mechanistic properties of organic biopolymers such as chitosan has received limited attention. The present study used a one-step synthetic method to obtain chitosan composites to monitor the uptake and release of a basic cationic dye (methylene blue) at two different pH values. Firstly, the composites were synthesized and characterized by Fourier Transform Infrared Spectroscopy (FTIR) and X-ray Diffraction (XRD) to ascertain their chemical identity. Adsorption studies were conducted suing methylene blue and these studies revealed that Acetic Acid-Chitosan (AA-CHI), Tetraethylorthosilicate-Chitosan (TEOS-CHI), Acetic Acid-Tetraethylorthosilicate-Chitosan (AA-TEOS-CHI), and Acetic Acid-Chitosan-Tetraethylorthosilicate (AA-CHI-TEOS) had comparatively lower percentage adsorbances in acidic media after 40 h, with AA-CHI adsorbing most of the methylene blue dye. In contrast, these materials recorded higher percentage adsorbances of methylene blue in the basic media. The release profiles of these composites were fitted with an exponential model. The R-squared values obtained indicated that the AA-CHI at pH ~ 2.6 and AA-TEOS-CHI at pH ~ 7.2 of methylene blue had steady and consistent release profiles. The release mechanisms were analyzed using Korsmeyer-Peppas and Hixson-Crowell models. It was deduced that the release profiles of the majority of the synthesized chitosan beads were influenced by the conformational or surface area changes of the methylene blue. This was justified by the higher correlation coefficient or Pearson’s R values (R ≥ 0.5) computed from the Hixson-Crowell model. The results from this study showed that two of the novel materials comprising acetic acid-chitosan and a combination of equimolar ratios of acetic acid-TEOS-chitosan could be useful pH-sensitive probes for various biomedical applications, whereas the other materials involving the two-step synthesis could be found useful in environmental remediation of toxic materials

    Half-life measurements of highly charged radionuclides

    No full text
    16th International Conference on the Physics of Highly Charged Ions (HCI), Ruprecht Karls Univ, Heidelberg, GERMANY, SEP 02-07, 2012International audienceIn recent years several measurements of the orbital electron capture half-lives of few-electron ions have been carried out employing the storage ring ESR at GSI. Hydrogen-like and helium-like Pr-140 and Pm-142 as well as hydrogen-like I-122 were studied. Half-lives of the corresponding fully ionized nuclides provide the three-body beta(+) decay constants

    Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

    No full text

    Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.

    No full text
    IMPORTANCE: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis. METHODS: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms. DISCUSSION: RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options. REGISTRATION: NCT05172024

    Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.

    No full text
    ImportanceSARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.MethodsRECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms.DiscussionRECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options.RegistrationNCT05172024
    corecore